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A commentary on
A human disease model of drug
toxicity-induced pulmonary edema in
a lung-on-a-chip microdevice
by Dongeun Huh et al. (2012). Sci. Transl.
Med. 4, 159ra147.
Acute lung injury (ALI) is a severe res-
piratory condition (high incidence and
mortality rates) caused by various eti-
ologies such as sepsis, shock, pneumo-
nia, heart failure, aspiration, and toxic
gas. Currently, there are no established
therapeutic strategies to reverse ALI dis-
ease progression. In addition, the very
high-concentration oxygen therapy widely
used to counteract ALI-induced hypox-
iemia could deteriorate the ALI (Kolliputi
andWaxman, 2009). In terms of economic
impact, ALI represents a significant cost,
estimated at 3.5–6 billion dollars annually
in the U.S. (Raghavendran et al., 2011).
One of the most outstanding hallmarks
of lung pathology in ALI is pulmonary
edema. It is preceded by high vascu-
lar pressure and/or increased alveolar-
capillary permeability, which cause the
influx of vascular leakage into the alve-
olar space that ultimately leads to pul-
monary edema. Additionally, sustained
pulmonary edema is also a major symp-
tom of ALI (Tamarapu Parthasarathy et al.,
2012). Hospitalization and mortality rates
associated with pulmonary edema are sig-
nificantly high. The development of new
drugs toward pulmonary edema and ALI is
at present hindered by the poor predictive
power of existing preclinical animal mod-
els. Besides that, currently available in vitro
experimental systems for investigating
pulmonary edema do not necessarily
reflect the structurally and functionally
intricate alveolar-capillary system, but
they consist of either epithelial cell or
vascular endothelial monolayer (Mehta
and Malik, 2006; Kolliputi et al., 2010,
2012). One approach to meeting this chal-
lenge is the development of innovative
and cost effective models to test drugs
and study multifaceted human physiol-
ogy in an organ-specific context. More
importantly, this approach should offer
the potential to design specific in vitro
human disease models that could revolu-
tionize drug development.
In the November 2012 issue of Sci.
Transl. Med., Huh et al. presented a
state-of-the-art experimental technique
to mimic the intricate vascular-alveolar
structure of the lung with a microchip
lined with living cells that reproduces
many of the features of a human lung
(Huh et al., 2012). The device framework
consists of four elastic polymer chan-
nels. Two channels are separated by a
thin, porous, flexible membrane lined
on one side with human lung epithelial
cells exposed to air and on the other side
with human pulmonary vascular endothe-
lial cells that are bathed in constantly
flowing culture media to mimic vascular
flow (Huh et al., 2010). The two verti-
cally apposed channels are flanked at both
sides by two hollow channels, through
which cyclic vacuum can be applied to
recreate breathing-induced shear stress.
Huh et al. first perfused the microvas-
cular channel with a clinically relevant
dose of interleukin-2 (IL-2), an anti-
cancer drug that can cause pulmonary
edema (Atkins et al., 1999; Briasoulis and
Pavlidis, 2001). Consistent with in vivo
IL-2-induced pulmonary edema, the
human lung-on-a-chip system success-
fully showed vascular leakage and flow
into the epithelial-sided air channel in
response to IL-2 treatment regardless
of added mechanical stress. Further,
Huh et al. demonstrated that immune
cells are not necessary for IL-2-induced
pulmonary edema and that mechanical
stretch, which alone had been shown
to have no detrimental effect on “lung”
permeability in the microdevice, greatly
exacerbates IL-2-induced human pul-
monary edema. These findings definitely
cast new insights into the mechanism
of pulmonary edema. And, importantly,
those new findings could not be readily
examined using other currently available
methods.
Next, the authors checked if the
IL-2-induced pulmonary edema-on-
a-chip model is applicable to testing
pharmacological agents. Using the
microchip, they first tested angiopoietin-1
(Ang-1), a known endothelial junc-
tion stabilizer (Peters, 1998). Consistent
with the previous reports, Ang-1 co-
administration with IL-2 completely
restored IL-2-induced loss of integrity
in vascular-epithelial barrier function.
Additionally, Huh et al. demonstrated that
a new transient receptor potential vanil-
loid 4 (TRPV4) ion channel inhibitor,
GSK2193874 (GlaxoSmithKline) com-
pletely blocked IL-2-induced increase in
vascular-epithelial permeability (Thodeti
et al., 2009). They also confirmed the
physiological relevance of these in vitro
results by duplicating IL-2-induced pul-
monary edema using an ex vivo mouse
ventilation-perfusion model.
This sophisticated microengineered
lung system is an epoch-making invention
that will facilitate better predictions on
how drugs will work in people, eventually
reducing the cost of drug development by
avoiding unnecessary animal experiments
or clinical trials. Also, it will certainly
add valuable data on disease mechanisms
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of the lung to complement routine cell
culture and animal experiments.
However, there are limitations to Huh
et al.’s microdevice: (1) The lung epithe-
lial cells used in the system are cancer
cells not primary cells, which raises the
question that the system might not closely
recapitulate the real pulmonary function;
(2) The system lacks interstitial fibroblasts
and alveolarmacrophages, cells involved in
maintenance of lung homeostasis (Griffin
et al., 1993; Shannon et al., 2001; Herold
et al., 2011); (3) The microchip-based
experiment, which requires well-equipped
laboratory and an experienced techni-
cian, would not be easily reproduced;
(4) In this report authors have not yet
established the chip capability to mimic
gas exchange between the air sac and
bloodstream, a key function of the lung,
though this chip may also be applied to
lung gas exchange model. It is certainly
unlikely that animal experiments would
totally be replaced by the chip. However,
the microdevice will undoubtedly facili-
tate both a better understanding of lung
diseases at the molecular level and rapid
testing of marketable drugs. Using the
lung-on-a-chip microdevice would def-
initely allow effective screening of an
enormous number of drugs and provide
sufficient time to focus on promising can-
didates. The cost reduction in drug devel-
opment would be followed by reduced
health care costs nationally and individ-
ually. Quick drug development will be a
blessing for those who are struggling with
refractory diseases. In the near future, a
microengineered chip equipped with key
organ functions could serve as valuable
resource in the pre-clinical evaluation of
drugs.
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